Researchers at Cedars-Sinai and UCLA found a method to determine whether cancer would metastasize or not. In the method, tumor cells that circulate in the bloodstream are analyzed. This is called "liquid biopsies," which means diagnostic tests that detect cancer biomarkers in the bloodstream. Compared to conventional diagnostic methods, liquid biopsies are less invasive and more comprehensive. Currently, commercial applications of liquid biopsies are used to improve treatment selection for late-stage cancers. In this work, the researchers utilized a chip with nanowires and coated with antibodies/proteins that recognize circulating tumor cells, the so-called NanoVelcro Chip. This powerful chip may allow physicians to monitor cancer-linked alterations in patients. Periodic blood tests present a less invasive way of monitoring cancer than repeated surgical procedures. What's more, the method used in this study is very effective. Prostate cancer in many cases grows slowly, does not reduce life expectancy, and may even not need treatment. But sometimes the cancer is aggressive and invasive. Treatment is required to slow disease progression. So it is important to determine which patients have more aggressive prostate cancer. It has been known that some cancer cells smaller nucleus than typical cancer cells, especially in patients with aggressive prostate cancer. The current study identified a link between very small nuclei and lung and liver metastases. In addition, these small nuclei were formed before cancer spread. Detecting very small nuclei could be a way to predict whether a patient would develop metastasis. In addition, Cusabio offers you antibodies like Biotin conjugated antibody.
